Lantern Pharma financials
$1.09−0.46%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$3.5M | -$3.4M | -$4.2M | -$4.3M | -$4.7M | -$4.8M | -$5.9M | -$5.2M | -$5.4M | -$5.7M | -$4.9M | -$3.5M |
| Net income | -$7.1M | -$3.3M | -$4.1M | -$4.2M | -$4.3M | -$4.5M | -$5.9M | -$4.5M | -$5.0M | -$5.4M | -$4.2M | -$3.2M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.57 | $-0.30 | $-0.36 | $-0.39 | $-0.40 | $-0.42 | $-0.54 | $-0.42 | $-0.46 | $-0.51 | $-0.39 | $-0.29 |
| EBITDA | -$3.5M | -$3.4M | -$4.2M | -$4.3M | -$4.6M | -$4.8M | -$5.9M | -$5.2M | -$5.4M | -$5.7M | -$4.9M | -$3.5M |
| Operating cash flow | -$2.9M | -$3.8M | -$2.8M | -$4.6M | -$3.9M | -$4.4M | -$4.0M | -$5.6M | -$5.2M | -$3.1M | -$3.4M | -$3.6M |
| Free cash flow | -$2.9M | -$3.8M | -$2.8M | -$4.6M | -$3.9M | -$4.4M | -$4.0M | -$5.6M | -$5.2M | -$3.1M | -$3.4M | -$3.6M |
| Diluted shares | 12.4M | 11.3M | 11.2M | 10.8M | 10.8M | 10.8M | 10.8M | 10.8M | 10.8M | 10.7M | 10.8M | 10.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $6.7M | $4.9M | $4.4M | $8.4M | $6.1M | $6.4M |
| Short-term investments | $701.1K | $1.4M | $5.7M | $4.0M | $9.8M | $13.3M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $8.6M | $7.2M | $11.0M | $13.6M | $17.4M | $21.1M |
| Total liabilities | $11.8M | $3.8M | $4.5M | $4.0M | $4.9M | $4.3M |
| Shareholders' equity | -$3.2M | $3.4M | $6.5M | $9.6M | $12.5M | $16.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology